GSK Pharma - Margins To Expand Beyond Consumer Healthcare Sale: Centrum Broking
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Centrum Broking Report
We attended the GlaxoSmithKline Pharmaceuticals Ltd.'s analyst meet. The management highlighted that the ongoing global specialty focus by Plc would enable India share of specialty going up over the coming decade.
The recent launch pipeline holds Shingrix, Trelegy, indication expansion for Nucala and Fluarix Tetra.
GSK Pharma's management is confident on Nucala upcoming expansion given the patient reach expansion by four times.
Considering the healthy launch pipeline, the management is confident of expanding Ebitda margins beyond the Cx transaction.
Valued at 16 times Ebitda and six times sales, closure is expected in FY22E.
We have adjusted for near-term Ebitda impact (1-1.5%) by reducing estimates by 4.5% for FY23E.
We are optimistic on future pipeline including Covid-19 vaccine.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.